Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/10/2019
Start Date:December 2014
End Date:December 2021
Contact:Michael Zelefsky, MD
Phone:212-639-6802

Use our guide to learn which trials are right for you!

The purpose of this study is to better understand prostate cancer changes after radiation
treatment, through magnetic resonance imaging (MRI). MRI is an imaging test that allows
doctors to see prostate gland without any operation procedures. It can help identifying the
tumors in the prostate. For patients with newly diagnosed prostate cancer, MRI may help
doctors manage treatment better and sooner.


Inclusion Criteria:

- Patients with biopsy proven (completed and/or reviewed at MSK) adenocarcinoma of the
prostate, who will undergo external beam radiotherapy using conventional fractionation
IGRT including moderate hypofractionated radiation, low rate brachytherapy alone,
brachytherapy (either high dose or low dose) combined with supplemental image guided
radiation (including IGRT, EBRT, and SBRT), SBRT, or proton radiotherapy.

- Age ≥ 18 years old

- Baseline MP-MRI, which is obtained at MSKCC Main Campus on the 3-Tesla Philips MRI
unit as part of the standard (clinical) staging assessment demonstrates at least one
dominant or visible lesion which measures > 0.5 cm in maximum axial diameter as
assessed on T2-weighted images.

- No prior history of androgen deprivation therapy within the last month. However
patients who will receive neoadjuvant and concurrent and adjuvant hormonal therapy
will be eligible.

- Willing to come to MSK Main Campus for baseline and follow-up MP-MRIs.

Exclusion Criteria:

- History of radical prostatectomy

- Patients who are unwilling or unable to undergo MRI including patients with
contraindications to MRI such as the presence of cardiac pacemakers or non-compatible
intracranial vascular clips, claustrophobia, inability to lie flat for the duration of
the study etc.

- Patients with a metallic hip implant, metallic implant or device in the pelvis or
ferromagnetic fiducial beacons (Calypso) that might distort local magnetic field and
compromise quality of MP-MRI

- Patients in which gadolinium contrast is contra-indicated.

- Metastatic disease
We found this trial at
8
sites
480 Red Hill Road
Middletown, New Jersey 07748
Phone: 212-639-6802
?
mi
from
Middletown, NJ
Click here to add this to my saved trials
Basking Ridge, New Jersey 07920
Phone: 212-639-6802
?
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Commack, New York 11725
Phone: 212-639-6802
?
mi
from
Commack, NY
Click here to add this to my saved trials
500 Westchester Avenue
Harrison, New York 10604
Phone: 212-639-6802
?
mi
from
Harrison, NY
Click here to add this to my saved trials
225 Summit Avenue
Montvale, New Jersey 07645
Phone: 212-639-6802
?
mi
from
Montvale, NJ
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Michael Zelefsky, MD
Phone: 212-639-6802
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Rockville Centre, New York 11570
Phone: 212-639-6802
?
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Uniondale, New York 11553
Phone: 212-639-6802
?
mi
from
Uniondale, NY
Click here to add this to my saved trials